July 22, 2020
Daiichi Sankyo’s antiplatelet agent prasugrel, sold under brand name Efient in Japan, met its primary endpoint in a Japan PIII study in patients with thrombotic stroke, showing a lower incidence of cerebral cardiovascular events compared to clopidogrel, the company said...read more